Epidermal growth factor: A new therapeutic target in glomerular disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1297-1304

  Flamant, Martin ^a   Bollée, Guillaume ^b,c   Hénique, Carole ^b,c   Tharaux, Pierre Louis ^b,c,d  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL PATHWAY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG USE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HUMAN; IMMUNOPATHOLOGY; KIDNEY BIOPSY; KIDNEY FIBROSIS; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

ANIMALS; EPIDERMAL GROWTH FACTOR; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84859357746     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs030     Document Type: Review

References (87)

1. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136 (Pubitemid 351398487)
2. Foster RR, Slater SC, Seckley J et al. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am J Pathol 2008; 173: 938-948
3. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-550 (Pubitemid 46193319)
4. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669 (Pubitemid 44484656)
5. Chen JX, Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 2008; 57: 3335-3343
6. Jeansson M, Gawlik A, Anderson G et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011; 121: 2278-2289
7. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol 2006; 17: 1253-1263 (Pubitemid 43673405)
8. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-418 (Pubitemid 44108124)
9. Duffield JS, Tipping PG, Kipari T et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207-1219 (Pubitemid 41541408)
10. Li S, Kurts C, Kontgen F et al. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med 1998; 188: 597-602 (Pubitemid 28369148)
11. Lloyd CM,Minto AW, DorfME et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185: 1371-1380 (Pubitemid 27172917)
12. Atkins RC, Nikolic-Paterson DJ, Song Q et al. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 1996; 7: 2271-2278 (Pubitemid 27465931)
13. Huang XR, Holdsworth SR, Tipping PG. Evidence for delayed-type hypersensitivity mechanisms in glomerular crescent formation. Kidney Int 1994; 46: 69-78 (Pubitemid 24210437)
14. Bolton WK, Innes DJ Jr, Sturgill BC et al. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int 1987; 32: 869-876 (Pubitemid 18015518)
15. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988; 11: 449-464
16. Lionaki S, Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin Immunopathol 2007; 29: 459-474 (Pubitemid 350077264)
17. Ohse T, Vaughan MR, Kopp JB et al. De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am J Physiol Renal Physiol 2010; 298: F702-F711
18. Thorner PS, Ho M, Eremina V et al. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008; 19: 495-502 (Pubitemid 351355393)
19. Ding M, Cui S, Li C et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006; 12: 1081-1087 (Pubitemid 44353390)
20. Bariety J, Bruneval P,Meyrier A et al. Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005; 68: 1109-1119 (Pubitemid 43246427)
21. Moeller MJ, Soofi A, Hartmann I et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004; 15: 61-67 (Pubitemid 38020698)
22. Besse-Eschmann V, Le Hir M, Endlich N et al. Alteration of podocytes in a murine model of crescentic glomerulonephritis. Histochem Cell Biol 2004; 122: 139-149 (Pubitemid 39222747)
23. Timoshanko JR, Kitching AR, Holdsworth SR et al. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol 2001; 12: 464-471 (Pubitemid 32180015)
24. Le Hir M, Keller C, Eschmann V et al. Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2001; 12: 2060-2071 (Pubitemid 32880342)
25. Ophascharoensuk V, Pippin JW, Gordon KL et al. Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int 1998; 54: 416-425 (Pubitemid 28357404)
26. Goumenos D, Tsomi K, Iatrou C et al. Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol Dial Transplant 1998; 13: 1652-1661 (Pubitemid 28306790)
27. Boucher A, Droz D, Adafer E et al. Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. Lab Invest 1987; 56: 526-533 (Pubitemid 17103634)
28. Guettier C, Nochy D, Jacquot C et al. Immunohistochemical demonstration of parietal epithelial cells and macrophages in human proliferative extra-capillary lesions. Virchows Arch A Pathol Anat Histopathol 1986; 409: 739-748 (Pubitemid 16043909)
29. Morley AR, Wheeler J. Cell proliferation within Bowman's capsule in mice. J Pathol 1985; 145: 315-327 (Pubitemid 15033385)
30. Hancock WW, Atkins RC. Cellular composition of crescents in human rapidly progressive glomerulonephritis identified using monoclonal antibodies. Am J Nephrol 1984; 4: 177-181 (Pubitemid 14111655)
31. Morita T, Suzuki Y, Churg J. Structure and development of the glomerular crescent. Am J Pathol 1973; 72: 349-368
32. Bollee G, Flamant M, Schordan S et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17: 1242-1250
33. Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res 2009; 315: 602-610
34. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516 (Pubitemid 44036456)
35. Jura N, Endres NF, Engel K et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137: 1293-1307
36. Graus-Porta D, Beerli RR, Daly JM et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655 (Pubitemid 27151960)
37. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225
38. Miettinen PJ, Berger JE, Meneses J et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376: 337-341
39. Higashiyama S, Abraham JA, Miller J et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936-939 (Pubitemid 21926188)
40. Nakano T, Raines EW, Abraham JA et al. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci USA 1994; 91: 1069-1073 (Pubitemid 24048510)
41. Raab G, KlagsbrunM. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997; 1333: F179-F199 (Pubitemid 28015313)
42. Higashiyama S, Lau K, Besner GE et al. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 1992; 267: 6205-6212
43. Flannery PJ, Spurney RF. Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp Nephrol 2006; 103: e109-e118 (Pubitemid 43952616)
44. Sunnarborg SW, Hinkle CL, Stevenson M et al. Tumor necrosis factoralpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002; 277: 12838-12845 (Pubitemid 34952648)
45. Hinkle CL, Sunnarborg SW, Loiselle D et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J Biol Chem 2004; 279: 24179-24188 (Pubitemid 38725278)
46. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26: 263-274
47. Naglich JG, Metherall JE, Russell DW et al. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 1992; 69: 1051-1061
48. Chenal A, Nizard P, Gillet D. Structure and function of diphtheria toxin: from pathology to engineering. J Toxicol-Tox Rev 2002; 21: 321-359
49. Higashiyama S, Nanba D.ADAM-mediated ectodomain shedding of HBEGF in receptor cross-talk. Biochim Biophys Acta 2005; 1751: 110-117 (Pubitemid 41033299)
50. Nishi E, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004; 22: 253-260 (Pubitemid 40123403)
51. Breyer MD, Redha R, Breyer JA. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol 1990; 259(4 Pt 2): F553-F558 (Pubitemid 20359091)
52. Coaxum SD, Garnovskaya MN, Gooz M et al. Epidermal growth factor activates Na(1/)H(1) exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta 2009; 1793: 1174-1181
53. Nakagawa T, Hayase Y, Sasahara M et al. Distribution of heparinbinding EGF-like growth factor protein and mRNA in the normal rat kidneys. Kidney Int 1997; 51: 1774-1779 (Pubitemid 27252746)
54. Groenestege WM, Thebault S, van der Wijst J et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117: 2260-2267 (Pubitemid 47219571)
55. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8: 387-394 (Pubitemid 46621761)
56. Homma T, Sakai M, Cheng HF et al. Induction of heparin-binding epidermal growth factor-like growth factor mRNA in rat kidney after acute injury. J Clin Invest 1995; 96: 1018-1025
57. Sakai M, Zhang M, Homma T et al. Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules. J Clin Invest 1997; 99: 2128-2138 (Pubitemid 27203769)
58. Singh AB, Sugimoto K, Harris RC. Juxtacrine activation of epidermal growth factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor protects epithelial cells from anoikis while maintaining an epithelial phenotype. J Biol Chem 2007; 282: 32890-32901 (Pubitemid 350159321)
59. Takemura T, Hino S, Murata Y et al. Coexpression of CD9 augments the ability of membrane-bound heparin-binding epidermal growth factor-like growth factor (proHB-EGF) to preserve renal epithelial cell viability. Kidney Int 1999; 55: 71-81 (Pubitemid 29004238)
60. Takemura T, Kondo S, Homma T et al. The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J Biol Chem 1997; 272: 31036-31042 (Pubitemid 27527550)
61. Humes HD, Cieslinski DA, Coimbra TM et al. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989; 84: 1757-1761 (Pubitemid 20016178)
62. Francois H, Placier S, Flamant M et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18: 926-928
63. Lautrette A, Li S, Alili R et al. Angiotensin II and EGF receptor crosstalk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11: 867-874 (Pubitemid 41161119)
64. Tharaux PL, Chatziantoniou C, Fakhouri F et al. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36: 330-336
65. Tharaux PL, Chatziantoniou C, Casellas D et al. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999; 99: 2185-2191 (Pubitemid 29196805)
66. Boffa JJ, Tharaux PL, Placier S et al. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 1999; 100: 1901-1908 (Pubitemid 29511144)
67. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y et al. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 2001; 60: 2153-2163 (Pubitemid 33070458)
68. Chen CH, Cheng TH, Lin H et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol 2006; 69: 1347-1355
69. Chansel D, Ciroldi M, Vandermeersch S et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 2006; 20: 1936-1938
70. Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-888
71. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 2004; 66: 1805-1814 (Pubitemid 41094304)
72. Advani A, Wiggins KJ, Cox AJ et al. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) 2011; 16: 573-581
73. Harris RC, Hoover RL, Jacobson HR et al. Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 1988; 82: 1028-1039
74. Paizis K, Kirkland G, Polihronis M et al. Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney Int 1998; 53: 1162-1171 (Pubitemid 28316876)
75. Paizis K, Kirkland G, Khong T et al. Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Kidney Int 1999; 55: 2310-2321 (Pubitemid 29256485)
76. Polihronis M, Murphy BF, Pearse MJ et al. Heparin-binding epidermal growth factor-like growth factor, an immediate-early gene for mesangial cells, is up-regulated in the Thy-1.1 model. Exp Nephrol 1996; 4: 271-278 (Pubitemid 26342896)
77. Takemura T, Murata Y, Hino S et al. Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis. J Pathol 1999; 189: 431-438 (Pubitemid 29489230)
78. Kirkland G, Paizis K, Wu LL et al. Heparin-binding EGF-like growth factor mRNA is upregulated in the peri-infarct region of the remnant kidney model: in vitro evidence suggests a regulatory role in myofibroblast transformation. J Am Soc Nephrol 1998; 9: 1464-1473 (Pubitemid 28354557)
79. Triantafyllopoulou A, Franzke CW, Seshan SV et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA 2010; 107: 3012-3017
80. Feng L, Garcia GE, Yang Y et al. Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats. J Clin Invest 2000; 105: 341-350 (Pubitemid 30094454)
81. Hao L, Du M, Lopez-Campistrous A et al. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94: 68-76 (Pubitemid 38064100)
82. Flamant M, Tharaux PL, Placier S et al. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17: 327-329
83. Simpson KJ, Selfors LM, Bui J et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 2008; 10: 1027-1038
84. Marikovsky M, Breuing K, Liu PY et al. Appearance of heparinbinding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993; 90: 3889-3893 (Pubitemid 23134131)
85. Peoples GE, Blotnick S, Takahashi K et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 1995; 92: 6547-6551
86. Blotnick S, Peoples GE, Freeman MR et al. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD41 and CD81 T cells. Proc Natl Acad Sci USA 1994; 91: 2890-2894
87. Harris R. EGFR signaling in podocytes at the root of glomerular disease. Nat Med 2011; 17: 1188-